Business Opportunities

FII-TO-FII TRADES: PNB traded at 7% premium

Trades between FIIs generated a volume of Rs 29 crore on the BSE Thursday-an increase of 40.27% from Rs 21 crore clocked on Wednesday. As many as five stocks witnessed trades of 6.44 lakh shares on Thursday. - Investment through PNs rising again - Sensex falls most in two weeks - Thermax bags Rs 478 cr order from Orissa-based firm - Jindal Drilling bags Rs 635 cr ONGC order - Promoter entities sell 2.73 cr shares in TCS - FIIs net sell Rs 459cr, DIIs net buy Rs 117cr Punjab National Bank was traded at highest premium of 6.72% on BSE with 31,229 shares changing hands at Rs 960.05 as against the spot price of Rs 899.60. CORPORATE BOND SPREADS TO DURATION-MATCHED US TREASURIES S&P credit ratings AA BB 31-May-07 0.67% 0.86% 1.14% 1-Dec-08 4.90% 5.94% 7.40% 9-Nov-09 1.26% 1.84% 2.62% Source: Barclays Capital US Corporates Index Union Bank of India was traded at second highest premium of 3.44% on BSE with 1.02 lakh shares changing hands at Rs 270.85 as against the spot price of Rs 261.85.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

News of the day
ISRO earned Rs 100 cr from foreign satellite launches
ISRO earned over Rs 100 crore in the last three years by launching satellites of other countries, Minister of State in PMO Prithviraj Chavan told the Lok Sabha today.
Popular Articles
payday loans online

Bank of Maharashtra net down 7%
Public sector lender Bank of Maharashtra reported a 7 per cent drop in net profit to Rs 112 crore for the quarter ended December 2009 against Rs 120.6 crore in the year-ago quarter. Net interest income, or the difference between interest earned and interest paid, grew 5 per cent to Rs 361 crore from Rs 343 crore in the December 2008 quarter.

Sun Pharma uses own plants for US market after after Caraco trouble
In spite of a major regulatory clampdown on its US subsidiary, Caraco, Mumbai-based Sun Pharmaceuticals is trying hard to keep its US market share intact. The company is relying on its own manufacturing facilities to deliver goods to the US market. All eight ANDAs (abbreviated new drug applications) for sales permission in the US filed during the first quarter of the current financial year (Q1FY2010) came from Sun’s facilities.